LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

    Chi, Victor / Pennington, Michael W / Norton, Raymond S / Tarcha, Eric J / Londono, Luz M / Sims-Fahey, Brian / Upadhyay, Sanjeev K / Lakey, Jonathan T / Iadonato, Shawn / Wulff, Heike / Beeton, Christine / Chandy, K George

    Toxicon : official journal of the International Society on Toxinology

    2011  Volume 59, Issue 4, Page(s) 529–546

    Abstract: ... a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin ... from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is ... being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 ...

    Abstract Electrophysiological and pharmacological studies coupled with molecular identification have revealed a unique network of ion channels--Kv1.3, KCa3.1, CRAC (Orai1 + Stim1), TRPM7, Cl(swell)--in lymphocytes that initiates and maintains the calcium signaling cascade required for activation. The expression pattern of these channels changes during lymphocyte activation and differentiation, allowing the functional network to adapt during an immune response. The Kv1.3 channel is of interest because it plays a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 trials in 2011. This review describes the journey that has led to the development of ShK-186.
    MeSH term(s) Amino Acid Sequence ; Animals ; Autoimmune Diseases/drug therapy ; Cell Differentiation/drug effects ; Cnidarian Venoms/pharmacokinetics ; Cnidarian Venoms/pharmacology ; Drug-Related Side Effects and Adverse Reactions ; Immunologic Factors/pharmacokinetics ; Immunologic Factors/pharmacology ; Ion Channels/metabolism ; Lymphocyte Activation/drug effects ; Molecular Sequence Data ; Protein Conformation ; Sea Anemones
    Chemical Substances Cnidarian Venoms ; Immunologic Factors ; Ion Channels ; ShK neurotoxin
    Language English
    Publishing date 2011-08-12
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 204479-1
    ISSN 1879-3150 ; 0041-0101
    ISSN (online) 1879-3150
    ISSN 0041-0101
    DOI 10.1016/j.toxicon.2011.07.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

    Chi, Victor / Pennington, Michael W / Norton, Raymond S / Tarcha, Eric J / Londono, Luz M / Sims-Fahey, Brian / Upadhyay, Sanjeev K / Lakey, Jonathan T / Iadonato, Shawn / Wulff, Heike / Beeton, Christine / Chandy, K. George

    Toxicon. 2012 Mar. 15, v. 59, no. 4

    2012  

    Abstract: ... a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin ... from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is ... being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 ...

    Abstract Electrophysiological and pharmacological studies coupled with molecular identification have revealed a unique network of ion channels—Kv1.3, KCa3.1, CRAC (Orai1 + Stim1), TRPM7, Clₛwₑₗₗ—in lymphocytes that initiates and maintains the calcium signaling cascade required for activation. The expression pattern of these channels changes during lymphocyte activation and differentiation, allowing the functional network to adapt during an immune response. The Kv1.3 channel is of interest because it plays a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 trials in 2011. This review describes the journey that has led to the development of ShK-186.
    Keywords Anthozoa ; B-lymphocytes ; autoimmune diseases ; calcium signaling ; immune response ; immunomodulators ; lymphocyte proliferation ; therapeutics
    Language English
    Dates of publication 2012-0315
    Size p. 529-546.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 204479-1
    ISSN 1879-3150 ; 0041-0101
    ISSN (online) 1879-3150
    ISSN 0041-0101
    DOI 10.1016/j.toxicon.2011.07.016
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  3. Article: Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

    Chi, Victor / Pennington, Michael W. / Norton, Raymond S. / Tarcha, Eric J. / Londono, Luz M. / Sims-Fahey, Brian / Upadhyay, Sanjeev K. / Lakey, Jonathan T. / Iadonato, Shawn / Wulff, Heike / Beeton, Christine / Chandy, K. George

    Toxicon

    Volume v. 59,, Issue no. 4

    Abstract: ... a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin ... from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is ... being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 ...

    Abstract Electrophysiological and pharmacological studies coupled with molecular identification have revealed a unique network of ion channels—Kv1.3, KCa3.1, CRAC (Orai1 + Stim1), TRPM7, Clₛwₑₗₗ—in lymphocytes that initiates and maintains the calcium signaling cascade required for activation. The expression pattern of these channels changes during lymphocyte activation and differentiation, allowing the functional network to adapt during an immune response. The Kv1.3 channel is of interest because it plays a critical role in subsets of T and B lymphocytes implicated in autoimmune disorders. The ShK toxin from the sea anemone Stichodactyla helianthus is a potent blocker of Kv1.3. ShK-186, a synthetic analog of ShK, is being developed as a therapeutic for autoimmune diseases, and is scheduled to begin first-in-man phase-1 trials in 2011. This review describes the journey that has led to the development of ShK-186.
    Keywords therapeutics ; lymphocyte proliferation ; immunomodulators ; autoimmune diseases ; Anthozoa ; immune response ; calcium signaling ; B-lymphocytes
    Language English
    Document type Article
    ISSN 0041-0101
    Database AGRIS - International Information System for the Agricultural Sciences and Technology

    More links

    Kategorien

To top